S. Heptinstall

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
S Heptinstall, S. Heptinstall, Stan Heptinstall*, S. M. Heptinstall, Stan Heptinstall, Stanley Heptinstall, S M Heptinstall
Publication record
245 papers · 11,279 citations · H-index 43

PAPERS

Remote platelet function testing using P-selectin expression in patients with recent cerebral ischaemia on clopidogrel
20203 citationsauthor #6
How does measurement of platelet P-selectin compare with other methods of measuring platelet function as a means of determining the effectiveness of antiplatelet therapy?
201913 citationsauthor #8
Circulating Microparticles in Patients with Symptomatic Carotid Disease Are Related to Embolic Plaque Activity and Recent Cerebral Ischaemia
20198 citationsauthor #3
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
2018144 citationsauthor #11
Baseline predictors of on-treatment platelet activity (as P-selectin expression) in patients in the triple aniplatelets for reducing dependency in ischaemic stroke (TARDIS) trial
20180 citationsauthor #5
Bath, Philip M. and May, Jane and Heptinstall, Stan (2018) Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders. Platelets
20181 citationsauthor #3
Platelet aggregation measured by single-platelet counting and using PFA-100 devices
201815 citationsauthor #2
Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders
201824 citationsauthor #3
Abstract TMP109: Remote Platelet Function Testing Using Measurement of P-selectin in Patients in the Triple Antiplatelets for Reducing Dependency in Ischaemic Stroke (TARDIS) Trial
20180 citationsauthor #4
Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
201814 citationsauthor #11
Novel strategies for assessing platelet reactivity.
201719 citationsauthor #2
Correction
20170 citationsauthor #5
James G. White MD, 1929–2016
20170 citationsauthor #1
Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack
201714 citationsauthor #11
A Remote Assay for Measuring Canine Platelet Activation and the Inhibitory Effects of Antiplatelet Agents
20177 citationsauthor #4
Baseline characteristics of the 3096 patients recruited into the ‘Triple Antiplatelets for Reducing Dependency after Ischemic Stroke’ trial
20178 citationsauthor #8
UDP-sugars activate P2Y14 receptors to mediate vasoconstriction of the porcine coronary artery
201723 citationsauthor #5
Abstract WP76: Baseline Characteristics of the 3,096 Patients Recruited Into the ‘Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke’ (TARDIS) Trial
20170 citationsauthor #8
A story of cooperation and friendship in Europe with good outcomes
20161 citationsauthor #1
PAMFix, a fixative developed to enable remote platelet function testing: uses and applications
20158 citationsauthor #1
An observational study investigating the effect of platelet function on outcome after colorectal surgery.
20157 citationsauthor #9
Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)
201526 citationsauthor #6
Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders
201447 citationsauthor #6
A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel
201434 citationsauthor #5
‘VASPFix’ for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists
201313 citationsauthor #5
How important is it to keep taking the aspirin?
20131 citationsauthor #1
Antiplatelet Agents: Current and Novel
20133 citationsauthor #1
Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers
201338 citationsauthor #7
Platelet activation by an extracellular adherence protein from Staphylococcus aureus acting via modulation of sulfhydryl groups on platelets.
20123 citationsauthor #1
PGE2 reverses Gs-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-Gs-mediated inhibition of platelet aggregation by interaction with EP4 receptors
201212 citationsauthor #4
The role of prostanoid receptors in mediating the effects of PGE3 on human platelet function
201214 citationsauthor #5
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes
201217 citationsauthor #3
Statement of retraction. Gupta A, Chandra T, Kumar A. "Platelet storage lesion: current proteomics approach".
20111 citationsauthor #1
Anticoagulants, Antiplatelets and Thrombolytics, 2nd Edition.
20110 citationsauthor #1
Anti-platelet therapy: ADP receptor antagonists
2011111 citationsauthor #2
P2Y12 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP
201132 citationsauthor #6
Obituary
20110 citationsauthor #2
PGE1 and PGE2 modify platelet function through different prostanoid receptors.
201166 citationsauthor #7
Adenosine Derived From ADP Can Contribute to Inhibition of Platelet Aggregation in the Presence of a P2Y12 Antagonist
201136 citationsauthor #5
The role of prostanoid receptors in mediating the effects of PGE2 on human platelet function
201062 citationsauthor #6
Abstracts presented at the Nottingham Platelet Conference, Platelets – Past, Present and Future
20101 citationsauthor #1
Prostaglandins and Other Lipid Mediators
20100 citationsauthor #7
Should critical care patients receive or remain on treatment with antiplatelet drugs?
20102 citationsauthor #2
Mode of action of P2Y12 antagonists as inhibitors of platelet function
201030 citationsauthor #7
Introducing a new type of article for Platelets: Spotlight articles
20100 citationsauthor #2
Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
201027 citationsauthor #5
Chocolate, Lifestyle, and Health
2009103 citationsauthor #5
Call for contributions to the new Methods section in Platelets
20090 citationsauthor #3
Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin
200944 citationsauthor #5
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3
200972 citationsauthor #8
Platelet function reduces significantly during the morning
200812 citationsauthor #5
The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function
2008100 citationsauthor #4
Multiple electrode aggregometry and P2Y12 antagonists
200844 citationsauthor #3
DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease
200868 citationsauthor #1
Raised levels of CD39 in leucocytosis result in marked inhibition of ADP-induced platelet aggregation via rapid ADP hydrolysis
20088 citationsauthor #6
Interactions Between Different P2Y12 Antagonists
20080 citationsauthor #2
Detection of P2Y14 protein in platelets and investigation of the role of P2Y14 in platelet function in comparison with the EP3 receptor
200824 citationsauthor #8
Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
200815 citationsauthor #9
Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y 12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes
200711 citationsauthor #4
HETEROCLITIN D, A COMPONENT OF PLANTS OF THE KADSURA SPECIES INHIBITS PAF-INDUCED PLATELET AGGREGATION, P-SELECTIN EXPRESSION AND PLATELET-LEUCOCYTE CONJUGATE FORMATION
20070 citationsauthor #3
Value of Platelet Activation Markers as Prothrombotic Risk Indicators
200710 citationsauthor #2
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
2007475 citationsauthor #4
PO-27 Raised levels of CD39 in leucocytosis result in marked inhibition of ADP-induced platelet aggregation via rapid ADP hydrolysis
20072 citationsauthor #1
COMPARISON OF THE EFFECTS OF THE P2Y14 RECEPTOR AGONIST UDP-GLUCOSE AND THE EP3 RECEPTOR AGONIST SULPROSTONE ON PLATELET FUNCTION
20070 citationsauthor #4
Enhanced platelet aggregation and activation under conditions of hypothermia
200757 citationsauthor #5
Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes
200614 citationsauthor #1
Cocoa Flavanols and Platelet and Leukocyte Function: Recent In Vitro and Ex Vivo Studies in Healthy Adults
200688 citationsauthor #1
Abstract 3292: AZD6140 Exerts Greater Inhibition of Platelet Aggregation than Clopidogrel in Patients with Stable Atherosclerotic Disease or Unstable Coronary Disease
20062 citationsauthor #5
SEMI‐AUTOMATED TRANSFORMATION TECHNIQUES FROM SINGLE AERIAL PHOTOGRAPHS
20061 citationsauthor #2
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
2006767 citationsauthor #3
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke
200654 citationsauthor #5
Antiplatelet therapy for stroke prevention
20051 citationsauthor #2
Current status of stroke prevention in patients with atrial fibrillation
200511 citationsauthor #3
Leukocytosis, vascular disease, and adenine nucleotide metabolism.
20052 citationsauthor #1
Leukocyte count and leukocyte ecto-nucleotidase are major determinants of the effects of adenosine triphosphate and adenosine diphosphate on platelet aggregation in human blood
200533 citationsauthor #7
Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
200522 citationsauthor #3
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke
200524 citationsauthor #8
Adenine nucleotide metabolism in human blood – important roles for leukocytes and erythrocytes
200570 citationsauthor #1
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes
200542 citationsauthor #3
CorrectionP-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist
20040 citationsauthor #5
Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry
200439 citationsauthor #5
Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke.
200415 citationsauthor #3
Platelet-monocyte interaction and GPIIb/IIIa blockade
20046 citationsauthor #4
Effects of anticoagulants used during blood collection on human platelet function.
200420 citationsauthor #2
Mechanisms Involved in Adenosine Triphosphate–Induced Platelet Aggregation in Whole Blood
200365 citationsauthor #5
Can the effects of clinical reperfusion fluids on platelet aggregation in vitro predict the effects of administration of such fluids in a clinical study ex vivo?
20030 citationsauthor #5
The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions
200323 citationsauthor #7
P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist
200333 citationsauthor #5
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease
2002145 citationsauthor #3
Platelet aggregation and intracellular calcium mobilisation responses are enhanced by cyclosporin A but not by pimecrolimus (SDZ ASM 981).
20027 citationsauthor #4
Transfer of Tissue Factor from Platelets to Monocytes: Role of Platelet-Derived Microvesicles and CD62P
2002131 citationsauthor #4
The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro
200237 citationsauthor #5
Comparison of the effects of the P2Y12 ADP-receptor antagonist (AR-C69931) and the GPIIb/IIIa antagonist GR 144053F on platelet-leukocyte conjugate formation.
20020 citationsauthor #8
Inhibition of ADP-induced P-selectin Expression and Platelet-Leukocyte Conjugate Formation by Clopidogrel and the P2Y12 Receptor Antagonist AR-C69931MX but not Aspirin
2002174 citationsauthor #4
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro
200156 citationsauthor #3
Hemostasis and thrombosis: basic principles and clinical practice, 4th edition
200122 citationsauthor #1
Effects of P2Y 1 and P2Y 12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood
2001113 citationsauthor #3
The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity
2000305 citationsauthor #6
Abstracts of papers presented at the 8th Erfurt Conference on Platelets, 25–28 June 2000, Augustiner-Kloster, Erfurt, Germany
20000 citationsauthor #2
Effects of cytochalasin H, a potent inhibitor of cytoskeletal reorganisation, on platelet function.
200023 citationsauthor #6

TIMELINE

1969 18 citations

1970 221 citations

1971 8 citations

1973 66 citations

1974 0 citations

1975 15 citations

1976 53 citations

1977 39 citations

1978 44 citations

1979 0 citations

1980 150 citations

1981 4 citations

1982 87 citations

1983 120 citations

1984 32 citations

1985 301 citations

1986 111 citations

1987 146 citations

1988 604 citations

1989 91 citations

1990 198 citations

1991 91 citations

1992 188 citations

1993 11 citations

1994 3,805 citations

1995 105 citations

1996 143 citations

1997 32 citations

1998 227 citations

1999 94 citations

2000 328 citations

2001 191 citations

2002 494 citations

2003 121 citations

2004 80 citations

2005 205 citations

2006 926 citations

2007 555 citations

2008 271 citations

2009 219 citations

2010 122 citations

2011 246 citations

2012 46 citations

2013 55 citations

2014 81 citations

2015 41 citations

2016 1 citations

2017 71 citations

2018 198 citations

2019 21 citations

2020 3 citations

S. Heptinstall

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT